uniQure N.V.
NASDAQ:QURE · NASDAQ Global Select
-$1.13 today
Vol 4.35M · Avg 1.75M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:QURE · Revenue to Net Income
Key Ratios
Analysis
$18.1M of revenue converted into -$208.9M of net income for the selected period. Gross margin is 77.4% and net margin is -1265.4%, showing how much revenue survives after costs and taxes. EPS is $-3.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M -40.6% | $27.1M +71.2% | $15.8M -85.1% | $106.5M -79.7% | $524.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.7M -90.8% | $18.3M +34.5% | $13.6M +307.7% | $3.3M -86.6% | $25.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $14.4M +63.9% | $8.8M +296.9% | $2.2M -97.9% | $103.1M -79.3% | $499.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.5% +57.1pp | 32.4% +18.4pp | 14.0% -82.9pp | 96.9% +1.6pp | 95.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $140.7M -2.2% | $143.8M -33.1% | $214.9M +8.7% | $197.6M +37.6% | $143.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $65.3M +28.9% | $50.7M -30.6% | $73.1M +33.6% | $54.7M -2.8% | $56.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $202.2M +4.7% | $193.1M -32.3% | $285.1M +15.7% | $246.3M +30.7% | $188.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $14.8M +16.8% | $12.6M +6.2% | $11.9M +39.4% | $8.5M +17.0% | $7.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$116.6M +27.5% | -$160.7M +36.5% | -$253.1M -134.3% | -$108.0M -133.9% | $319.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -724.2% -131.5pp | -592.7% +1004.8pp | -1597.6% -1496.1pp | -101.4% -162.3pp | 60.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$187.8M -1.9% | -$184.3M +34.8% | -$282.9M -97.6% | -$143.2M -146.1% | $310.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1166.8% -487.2pp | -679.6% +1105.9pp | -1785.5% -1651.0pp | -134.4% -193.7pp | 59.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $17.0M -20.8% | $21.4M +9.5% | $19.6M +3112.2% | $609.0K +275.9% | $162.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $62.0M -2.7% | $63.7M +53.4% | $41.6M +255.1% | $11.7M +56.6% | $7.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$5.5M +89.6% | -$52.8M -123.1% | -$23.7M -259.0% | $14.9M -32.8% | $22.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$193.3M +18.5% | -$237.1M +22.6% | -$306.6M -139.0% | -$128.3M -138.5% | $332.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1201.0% -326.6pp | -874.4% +1060.6pp | -1935.0% -1814.5pp | -120.5% -184.0pp | 63.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.6M +131.8% | $2.4M +26.4% | $1.9M +230.7% | -$1.5M -145.7% | $3.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$199.0M +16.9% | -$239.6M +22.3% | -$308.5M -143.3% | -$126.8M -138.5% | $329.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1236.0% -352.6pp | -883.4% +1063.7pp | -1947.1% -1828.0pp | -119.1% -182.0pp | 62.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +29.7% | -$5 +24.0% | -$6 -138.7% | -$3 -137.8% | $7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +29.7% | -$5 +24.0% | -$6 -138.7% | -$3 -138.5% | $7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.5M +18.2% | $48.6M +2.1% | $47.7M +2.0% | $46.7M +1.6% | $46.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.5M +18.2% | $48.6M +2.1% | $47.7M +2.0% | $46.7M -0.2% | $46.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.83B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.65B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.50B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$2.10B
Nuvation Bio Inc.
NYSE:NUVB
$1.89B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.84B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.67B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.50B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does QURE generate?
uniQure N.V. (QURE) reported $16.10M of revenue in fiscal 2025.
Is QURE profitable?
uniQure N.V. (QURE) reported -$198,971,000.00 of net income, with a net margin of -1236.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.